EU's Highest Court Advised Prostaglandin Eyelash Serum Is Not A Medicine Per Se
Executive Summary
Just because the use of a substance in a cosmetic product, in this case prostaglandin-derivative methylamide-dihydro-noralfaprostal, has a physiological effect does not mean it's a medicinal product by function, advises the Advocate General of the Court of Justice of the EU in a recent opinion. While the opinion does not bind the CJEU to any decision, it may impact discussions elsewhere with regards to these substances, for example in the US.
You may also be interested in...
CIR Expert Panel’s Prostaglandin Review: Uncertainties Persist Around ‘Eye Makeup’ Ingredients
Cosmetic Ingredient Review’s expert panel issued an insufficient data announcement for two prostaglandin analogs at its June meeting in Washington. The group is reviewing the substances – related to the active ingredient in Allergan’s prescription drug Latisse for eyelash growth – after the US FDA indicated that they could be used lawfully in cosmetic products.
CIR’s 161st Expert Panel Meeting: Much Ado About Airbrush Cosmetics; Prostaglandins Make 2023 Priorities
Exactly what is in airbrush-delivered cosmetics, and how they are used by consumers, are not well understood by Cosmetic Ingredient Review, its expert panel, or the US FDA. At their June meeting, CIR’s independent experts debated who should be responsible for assessing airbrush cosmetics and how safety unknowns should be communicated.
Making Cosmetics Reform Beneficial For All; Former FDA Cosmetics Director Yearns For ‘Serious Sit-Down’
Federal legislative reform is an historic opportunity not only to strengthen the US FDA’s oversight of the cosmetics sector, but also to modernize the industry and its value proposition to consumers. John Bailey, independent advisor for cosmetics and colors at EAS Consulting Group, is confident there’s a way to do all, but "serious" stakeholder negotiations are needed.